Register

Register

Register here to subscribe to the print and digital copies of PRIME Journal and get unrestricted access to all news, analysis and peer-reviewed content on our website.

Register or Find out more

Menu

PRIME Journal

Search Account

Already Registered?

Forgotten Password?

Register for free

Register for FREE and get unrestricted access to all news, analysis and peer-reviewed content, and create your own tailored alerts.

Register

USC’s Phase II clinical trial proves ProLon FMD is the first food technology that treats ageing and reduces risk factors for multiple age-related diseases

By Press Release / Posted in Anti-Ageing on May 18, 2017

A new study finds that providing the body with a temporary, specifically formulated Fasting Mimicking Diet (FMD™) called ProLon® causes…

A new study finds that providing the body with a temporary, specifically formulated Fasting Mimicking Diet (FMD™) called ProLon® causes cellular changes normally generated by several days of consecutive water-only fasting and may increase health and lifespan by partially turning back the aging clock.

After publishing in Cell Metabolism the animal results showing that this FMD reduces incidence of cancer and inflammatory diseases and extends lifespan, the Longevity Institute at the University of Southern California (USC) today publishes in Science Translational Medicine the results of a randomized Phase II clinical trial demonstrating that ProLon targets the aging process and reduces risk factors for age related diseases such as diabetes, cancer, and cardiovascular disease in humans. These effects are believed to be caused by an increase in stem cell number and regeneration. Screen Shot 2017-05-18 at 09.39.50

This 100-participant landmark clinical study stems from over two decades of molecular, animal, and clinical testing at USC’s Valter Longo laboratory under the sponsorship of the National Institute of Aging and the National Cancer Institute of the NIH.

In the current publication, researchers tested the effects of three monthly ProLon cycles on metabolic markers and risk factors associated with aging and age‐related diseases. Each ProLon cycle lasts five consecutive days and does not require alteration to lifestyle during the remaining days of the month. Findings in humans were consistent with mouse studies showing a spike in circulating stem cells and delay in biological aging by promoting regeneration in multiple systems. Body weight, BMI, total body fat, trunk fat, waist circumference, systolic and diastolic blood pressure, cholesterol, insulin‐like growth factor 1 (IGF‐1), and c-reactive protein (a marker of inflammation) were significantly reduced, particularly in participants at risk for diseases, while relative lean body mass (muscle and bone mass) was increased. Low levels of IGF-1 are associated with a lower risk of cancer and diabetes. No serious adverse effects were reported.

 

Water-only fasting for several consecutive days (called periodic fasting) may have some beneficial effects. However, water-only fasting carries many risks including hypoglycemia, hypotension, and/or gallstones. Furthermore, most people are unable to adhere to water-only fasting or very low calorie diets. The ProLon nutri-technology allowed participants to benefit from the positive effects of fasting while allowing them to consume food. ProLon’s five-day “fasting with food™” program features meals ranging from 770 to 1,100 calories per day and is clinically proven to:

  • promote effects on a wide range of markers that contribute to aging, such as cholesterol, triglyceride, blood pressure, inflammation, IGF-1, and fasting blood glucose;
  • help people lose an average of five pounds of fat and 1.2 inches of waist circumference, while preserving lean body mass (muscle and bone); and
  • provide the body with healthy, plant-based ingredients (free of any additives or chemicals) including essential vitamins, minerals and amino acids, low-protein, low-carbohydrate, and high good fat ingredients.

Over 3,600 ProLon boxes have been consumed during the pilot launch phase and market research shows an over 86% satisfaction rate and 92% recommendation rate. ProLon is intended for use by individuals who want to optimize their health and wellbeing, by overweight or obese individuals who want to manage their weight in an easy and healthy way, and by people who have abnormal levels of biomarkers for aging and age-related conditions. It is available through healthcare providers and at www.prolonfmd.com.

Press Release

, ,

More articles by Press Release

Analysis

Opinion

x

Send to a colleague

  • Your details

  • Your colleague's details

  • Leave a message?